tbuckley/cabot-search huggingface dataset:
1257O Durability of clinical benefit and biomarkers in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with AMG 510 (sotorasib)
Authors: D.S. Hong, Y-J. Bang, F. Barlesi, G.A. Durm, G.S. Falchook, R. Govindan, G.K. Dy, K. Park, J.H. Strickler, T.F. Burns, J. Kim, A. Ang, J.R. Lipford, G. Ngarmchamnanrith, A. Anderson, B.T. Li
Journal: Annals of Oncology (2020)
279MO Divergent evolution of overall survival across metastatic breast cancer (MBC) subtypes in the nationwide ESME real life cohort 2008-2016
Authors: S. Delaloge, A. Antoine, M. Debled, W. Jacot, P.H. Cottu, V.C. Dieras, F. Dalenc, A. Gonçalves, A. Patsouris, M.A. Mouret Reynier, A. Mailliez, F. Clatot, C. Levy, J-M. Ferrero, I. Desmoulins, L. Uwer, M. Robain, T. Bachelot, E. Brain, D. Perol
Journal: Annals of Oncology (2020)
625P Pembrolizumab (pembro) plus enzalutamide (enza) in patients with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort C update
Authors: L. Mourey, H.J. Conter, N. Shore, W.R. Berry, P.C. Fong, J.M. Piulats, L.J. Appleman, T. Todenhöfer, G. Gravis, B. Laguerre, H. Gurney, M. Retz, E. Romano, J.S. de Bono, A.E. Kam, U. Emmenegger, H. Wu, P. Qiu, C. Schloss, E.Y. Yu
Journal: Annals of Oncology (2020)
634P Impact of metastatic lymph node burden on survival in patients with mHSPC from the "docetaxel comparison” of the STAMPEDE trial
Authors: A.M. Haran, A. Ali, A. Hoyle, T. Hambrock, Y. Jain, C. Brawley, C. Amos, J. Calvert, G. Attard, H. Douis, M.K. Parmar, M.R. Sydes, N.D. James, N.W. Clarke
Journal: Annals of Oncology (2020)
545P Preclinical profile of EPI-7386, a second-generation N-terminal domain androgen receptor inhibitor for the treatment of prostate cancer
Authors: R. Le Moigne, N.H. Hong, P. Pearson, V. Lauriault, C.A. Banuelos, N.R. Mawji, T. Tam, J. Wang, P. Virsik, R.J. Andersen, M.D. Sadar, H-J. Zhou, A. Cesano
Journal: Annals of Oncology (2020)
533MO Phase Ib study of BI 836880, a VEGF/Ang2-blocking nanobody®, in combination with BI 754091, an anti-PD-1 antibody: Initial results in patients (pts) with solid tumours
Authors: N. Girard, M. Wermke, F. Barlesi, D-W. Kim, F. Ghiringhelli, H.T. Landsteiner, G. Jayadeva, J. Alt, B. Hackanson
Journal: Annals of Oncology (2020)
330P Comparative effectiveness of ribociclib plus fulvestrant (RIB+FUL) versus palbociclib plus letrozole (PAL+LET) as first-line (1L) treatment (Tx) of HR+/HER2− advanced breast cancer (ABC) assessed by matching-adjusted indirect comparison (MAIC)
Authors: P.A. Fasching, T. Delea, Y-S. Lu, R. DeBoer, S.A. Hurvitz, A. Moynahan, D. Chandiwana, B. Lanoue, H. Hu, A. Thuerigen, J. O'Shaughnessy
Journal: Annals of Oncology (2020)
Extracellular vesicles derived from Krüppel-Like Factor 2-overexpressing endothelial cells attenuate myocardial ischemia-reperfusion injury by preventing Ly6C<sup>high</sup> monocyte recruitment
Authors: Shuaihua Qiao, Wenfeng Zhang, Yong Yin, Zhonghai Wei, Fu Chen, Jinxuan Zhao, Xuan Sun, Dan Mu, Jun Xie, Biao Xu
Journal: Theranostics (2020)

Background: The ischemia/reperfusion (I/R) process in patients with ST-segment elevation myocardial infarction (STEMI) triggers an immune response, resulting in myocyte death. Krüppel-Like Factor 2 (KLF2), which is highly expressed in endothelial cells (ECs) under laminar flow, exerts anti-inflammatory effects. In this study, we explored the role of small extracellular vesicles (EVs) from KLF2-overexpressing ECs (KLF2-EVs) in the immunomodulation and its implications in myocardial I/R injury. Methods and Results: The small EVs were isolated from KLF2-overexpressing ECs' supernatant using gradient centrifugation. Mice were subjected to 45 min of ischemia followed by reperfusion, and KLF2-EVs were administrated through intravenous injection. KLF2-EVs ameliorated I/R injury and alleviated inflammation level in the serum and heart. We employed the macrophage depletion model and splenectomy and showed that Ly6Chigh monocyte recruitment from bone marrow was the main target of KLF2-EVs. miRNA-sequencing of KLF2-EVs and bioinformatics analysis implicated miRNA-24-3p (miR-24-3p) as a potent candidate mediator of monocyte recruitment and CCR2 as a downstream target. miR-24-3p mimic inhibited the migration of Ly6Chigh monocytes, and miR-24-3p antagomir reversed the effect of KLF2-EVs in myocardial I/R. Conclusion: Our data demonstrated that KLF2-EVs attenuated myocardial I/R injury in mice via shuttling miR-24-3p that restrained the Ly6Chigh monocyte recruitment. Thus, KLF2-EVs could be a potential therapeutic agent for myocardial I/R injury.
147P Exosomes microRNA sequencing identifies miR-363-5p as non-invasive biomarker of axillary lymph node metastasis and prognosis in breast cancer
Authors: X. Wang, T. Qian, S. Bao, H. Zhao, Z. Xing, H. Gao, Y. Li, J. Wang, M. Zhang, None X. Meng, C. Wang, J. Liu, M. Zhou, X. Wang
Journal: Annals of Oncology (2020)
1566TiP PRODIGE 65 - UCGI 36 - GEMPAX : A unicancer phase III randomized study evaluating gemcitabine and paclitaxel versus gemcitabine alone after FOLFIRINOX failure or intolerance in metastatic pancreatic ductal adenocarcinoma
Authors: C. de la Fouchardiere, P. Hammel, S. Launay, A. Vienot, J. Raimbourg, H. Perrier, L. Evesque, F. Ghiringhelli, M. Jary, T. Aparicio, F. Hociné, C. Neuzillet, D. Botsen, J.M. Phelip, A. Peytier, P. Michel, C. Cropet, N. Lachaux, S. Chabaud, L. Dahan
Journal: Annals of Oncology (2020)
73P Long-term follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer
Authors: C. Yoo, D-Y. Oh, H.J. Choi, M. Kudo, M. Ueno, S. Kondo, L-T. Chen, M. Osada, C. Helwig, I. Dussault, M. Ikeda
Journal: Annals of Oncology (2020)
761P Impact of the combination of durvalumab (MEDI4736) plus olaparib (AZD2281) administered prior to surgery in the molecular profile of resectable urothelial bladder cancer. NEODURVARIB trial
Authors: J.F. Rodriguez-Moreno, G. de Velasco, C. Alvarez-Fernandez, R. Collado, R. Fernandez-Rodriguez, S. Vazquez Estevez, J.A. Virizuela Echaburu, P. Gajate Borau, A. Font, N. Lainez, E. Sevillano Fernandez, S. Ruiz, L. Beltran, C. Rodriguez-Antona, P. Berraondo, J. Garcia-Donas
Journal: Annals of Oncology (2020)
1636P METASYN: Patterns of care and outcomes of 387 METAstatic SYNovial sarcoma: Real-life data from the French Sarcoma Group (GSF/GETO)
Authors: C. Moreau-Bachelard, M. Toulmonde, A. Le Cesne, M. Brahmi, A. Italiano, O. Mir, S. Piperno-Neumann, V. Laurence, N. Firmin, C.M. Chevreau, F. Bertucci, B. Narciso, P. Dubray-Longeras, C. Delcambre, E. Saada-Bouzid, P. Soulié, C. Perrin, J-Y. Blay, E. Bompas
Journal: Annals of Oncology (2020)
1746P Impact of PD-1/PD-L1 blockade therapy in COVID-19 infected cancer patients (pts) hospitalization: Results of an Italian study in the province of Modena and Reggio Emilia during SARS-CoV-2 outbreak
Authors: A. Damato, A. Spallanzani, A. Berselli, G. Rovesti, S. Benatti, G. Luppi, C. Pinto
Journal: Annals of Oncology (2020)
Arthroscopic partial meniscectomy for degenerative meniscus tears in middle age patients: why surgeons should change their approach
Authors: Lars Engebretsen, Gilbert Moatshe
Journal: British Journal of Sports Medicine (2020)

In the interesting linked article,1 authors Dr Raine Sihvonen and colleagues suggest that arthroscopic partial meniscectomy (APM) may lead to long-term harms (by increasing the risk of knee osteoarthritis (OA)) with no clear benefits in patient-reported outcomes. This study was a carefully executed multicentre, randomised, participant-blinded and outcome assessor-blinded, placebo-surgery controlled efficacy trial in participants aged 35 to 65 years who had had knee symptoms for more than 3 months, consistent with the diagnosis of a degenerative medial meniscus tear.1 Participants had not responded to conventional conservative treatment and were free of advanced knee osteoarthritis. A degenerative meniscus tear was verified on both MRI and knee arthroscopy. Patients with an obvious traumatic onset of symptoms or a recent history of a locked knee were excluded. Participants were followed up by questionnaires at 2, 6, 12, 24, 36, 48 and 60 months. At the 24-month and 60-month follow-up, standardised clinical examinations were carried out to …
960P A real-world clinical outcomes and prognostic factors in Japanese patients with recurrent or metastatic squamous cell carcinoma of head and neck treated with chemotherapy plus cetuximab: A prospective observation study (JROSG12-2)
Authors: T. Yokota, Y. Ota, H. Fujii, T. Kodaira, M. Shimokawa, T. Nakashima, N. Monden, A. Homma, S. Ueda, T. Akimoto
Journal: Annals of Oncology (2020)
600TiP A first-in-human study of, NUC-7738, a 3'-dA phosphoramidate, in patients with advanced solid tumours (NuTide:701)
Authors: S. Symeonides, F. Aroldi, N. Md Harris, S. Kestenbaumum, R. Plummer, S. Blagden
Journal: Annals of Oncology (2020)
Gastrointestinal Complications in Critically Ill Patients With and Without COVID-19
Authors: Mohamad El Moheb, Leon Naar, Mathias A. Christensen, Carolijn Kapoen, Lydia R. Maurer, Maha Farhat, Haytham M. A. Kaafarani
Journal: JAMA (2020)

Sravanthi Parasa, MD; Madhav Desai, MD, MPH; Viveksandeep Thoguluva Chandrasekar, MD; Harsh K. Patel, MD; Kevin F. Kennedy, MS; Thomas Roesch, MD; Marco Spadaccini, MD; Matteo Colombo, MD; Roberto Gabbiadini, MD; Everson L. A. Artifon, MD; Alessandro Repici, MD; Prateek Sharma, MD
1957P Evaluation of a digital treatment assignment system on whole-exome sequencing data of pediatric cancer patients
Authors: B. Vodicska, J. Déri, E. Várkondi, P. Filotas, D. Tihanyi, C. Hegedues, C. Kiss, I. Szegedi, K. Bartyik, K.M. Gábor, R. Simon, P. Hauser, G. Péter, M. Garami, I. Petak
Journal: Annals of Oncology (2020)
151P Prevalence of Anaplastic Lymphoma Kinase (ALK)+ Non-Small Cell Lung Cancer (NSCLC) in the Middle East and North Africa (MENA)
Authors: A.R. Jazieh, R. Gaafar, H. Errihani, H. Jaafar, F. Al Dayel, A. Bahnassy, H. El Kadi, M. Magdy Abdallah, A. Bearz
Journal: Annals of Oncology (2020)
1828P Effect of serum albumin/globulin ratio in combination with MASCC and CISNE risk score on febrile neutropenia mortality
Authors: O. Yazıcı, O. Sutcuoglu, O. Akdogan, B. Kurt Inci, F. Gürler, N. Özdemir Yıldırım
Journal: Annals of Oncology (2020)
1198P Digital droplet PCR-based detection of TP53 mutations in circulating DNA for the disease monitoring in patients with hereditary ovarian or breast cancer
Authors: E. Imyanitov, S. Aleksakhina, T. Gorodnova, E. Anisimova, L. Gigolayeva, K. Zagorodnev, I. Berlev, P. Krivorotko, G. Yanus, A. Iyevleva
Journal: Annals of Oncology (2020)
538P Vemurafenib in non-melanoma V600 and non-V600 BRAF mutated cancers: Results of the AcSé basket trial
Authors: P. Tomasini, J. Mazieres, C. Cropet, X.G. Troussard, D. Malka, I.L. Ray-Coquard, S. Leboulleux, A. Fléchon, B. Arnulf, M. Cancel, I. Bieche, S. Collot, S. Taieb, G. Garcia, A-M. Mandache, N. Colignon, M. Gavrel, M. Jimenez, N. Hoog-Labouret, J-Y. Blay
Journal: Annals of Oncology (2020)
818P Veliparib with carboplatin and paclitaxel in frontline high-grade serous ovarian cancer (HGSOC): Efficacy and safety of paclitaxel weekly and every 3 weeks in the VELIA study
Authors: A. Okamoto, G. Fleming, M. Bookman, M.F. Brady, E.M. Swisher, K.D. Steffensen, N.G. Cloven, T. Enomoto, D.M. O'Malley, L. Van Le, K.S. Tewari, J.N. Barlin, W. Bradley, K.N. Moore, J. Chan, M. Wu, H. Hashiba, M.H. Dinh, R.L. Coleman, C. Aghajanian
Journal: Annals of Oncology (2020)
Inactivation of tumor suppressor gene Clusterin leads to hyperactivation of TAK1-NF-κB signaling axis in lung cancer cells and denotes a therapeutic opportunity
Authors: Zhipeng Chen, Zhenzhen Fan, Xiaowei Dou, Qian Zhou, Guandi Zeng, Lu Liu, Wensheng Chen, Ruirui Lan, Wanting Liu, Guoqing Ru, Lei Yu, Qing-Yu He, Liang Chen
Journal: Theranostics (2020)

Purpose: Clinical success of precision medicine is severely limited by de novo or acquired drug resistance. It remains a clinically unmet need to treat these patients. Tumor suppressor genes (TSGs) play a critical role in tumorigenesis and impact the therapeutic effect of various treatments. Experimental Design: Using clinical data, in vitro cell line data and in vivo mouse model data, we revealed the tumor suppressive role of Clusterin in lung cancer. We also delineated the signaling cascade elicited by loss of function of CLU in NSCLC cells and tested precision medicine for CLU deficient lung cancers. Results:CLU is a potent and clinically relevant TSG in lung cancer. Mechanistically, CLU inhibits TGFBR1 to recruit TRAF6/TAB2/TAK1 complex and thus inhibits activation of TAK1- NF-κB signaling axis. Lung cancer cells with loss of function of CLU show exquisite sensitivity to TAK1 inhibitors. Importantly, we show that a significant portion of Kras mutation positive NSCLC patients are concurrently deficient of CLU and that TAK1 kinase inhibitor synergizes with existing drugs to treat this portion of lung cancers patients. Conclusions: Combinational treatment with TAK1 inhibitor and MEK1/2 inhibitor effectively shrank Kras mutation positive and CLU deficient NSCLC tumors. Moreover, we put forward a concept that loss of function of a TSG rewires signaling network and thereby creates an Achilles' heel in tumor cells which could be exploited in precision medicine.
Models of Idiosyncratic Drug-Induced Liver Injury
Authors: Tsuyoshi Yokoi, Shingo Oda
Journal: The Annual Review of Pharmacology and Toxicology (2020)

Drug-induced liver injury (DILI) is a leading cause of attrition during the early and late stages of drug development and after a drug is marketed. DILI is generally classified as either intrinsic or idiosyncratic. Intrinsic DILI is dose dependent and predictable (e.g., acetaminophen toxicity). However, predicting the occurrence of idiosyncratic DILI, which has a very low incidence and is associated with severe liver damage, is difficult because of its complex nature and the poor understanding of its mechanism. Considering drug metabolism and pharmacokinetics, we established experimental animal models of DILI for 14 clinical drugs that cause idiosyncratic DILI in humans, which is characterized by the formation of reactive metabolites and the involvement of both innate and adaptive immunity. On the basis of the biomarker data obtained from the animal models, we developed a cell-based assay system that predicts the potential risks of drugs for inducing DILI. These findings increase our understanding of the mechanisms of DILI and may help predict and prevent idiosyncratic DILI due to certain drugs.
1900P RAMES trial: A multicentre, double-blind, randomized, phase II study on gemcitabine plus ramucirumab versus gemcitabine alone as second-line treatment for advanced malignant pleural mesothelioma (MPM)
Authors: M. Pagano, G.L. Ceresoli, P.A. Zucali, G. Pasello, M.C. Garassino, F. Grosso, M. Tiseo, H.J. Soto Parra, F. Zanelli, F. Cappuzzo, F. Grossi, F. De Marinis, P. Pedrazzoli, None C. bonelli, A. Berselli, N. Normanno, C. Pinto
Journal: Annals of Oncology (2020)
Cholesterol Pathway Inhibition Induces TGF-β Signaling to Promote Basal Differentiation in Pancreatic Cancer
Authors: Linara Gabitova-Cornell, Aizhan Surumbayeva, Suraj Peri, Janusz Franco-Barraza, Diana Restifo, Nicole Weitz, Charline Ogier, Aaron R. Goldman, Tiffiney R. Hartman, Ralph Francescone, Yinfei Tan, Emmanuelle Nicolas, Neelima Shah, Elizabeth A. Handorf, Kathy Q. Cai, Alana M. O'Reilly, Ido Sloma, Rachel Chiaverelli, Richard A. Moffitt, Vladimir Khazak, Carolyn Y. Fang, Erica A. Golemis, Edna Cukierman, Igor Astsaturov
Journal: Cancer Cell (2020)
297P SP142 immunohistochemistry (IHC) PD-L1 inter- and intra-pathologist agreement in triple negative breast carcinoma (TNBC)
Authors: J-M. Pang, B. Castles, D.J. Byrne, P. Button, S. Lakhani, V. Sivasubramaniam, W. Cooper, J. Armes, E. Millar, W. Raymond, S. Roberts-Thomson, B. Kumar, M.L. Burr, C. Selinger, K. Harvey, C. Chan, J. Beith, S.A. O'Toole, S.B. Fox
Journal: Annals of Oncology (2020)
108P Pembrolizumab in pre-treated advanced non-small cell lung cancer (NSCLC) patients (pts): Impact of blood-based biomarkers on survival outcomes
Authors: A. Ortega Franco, R. Tay, H. Raja, C.J. Ackermann, M. Carter, C. Lindsay, S. Hughes, L. Cove-Smith, P. Taylor, Y. Summers, F.H. Blackhall, R. Califano
Journal: Annals of Oncology (2020)
Vitamin A and Retinoic Acid in Cognition and Cognitive Disease
Authors: Marta U. Wołoszynowska-Fraser, Azita Kouchmeshky, Peter McCaffery
Journal: Annual Review of Nutrition (2020)

The history of vitamin A goes back over one hundred years, but our realization of its importance for the brain and cognition is much more recent. The brain is more efficient than other target tissues at converting vitamin A to retinoic acid (RA), which activates retinoic acid receptors (RARs). RARs regulate transcription, but their function in the cytoplasm to control nongenomic actions is also crucial. Controlled synthesis of RA is essential for regulating synaptic plasticity in regions of the brain involved in learning and memory, such as the hippocampus. Vitamin A deficiency results in a deterioration of these functions, and failure of RA signaling is perhaps associated with normal cognitive decline with age as well as with Alzheimer's disease. Further, several psychiatric and developmental disorders that disrupt cognition are also linked with vitamin A and point to their possible treatment with vitamin A or RA.
1346P Comparison of clinical outcomes of patients with METΔex14 NSCLC treated with first-line capmatinib in the GEOMETRY mono-1 study with those of a cohort of real-world patients
Authors: J. Wolf, J.W. Neal, A.S. Mansfield, V. Doban, H. Kanakamedala, W-H. Wu, A. Joshi, E. de Jong, M. Giovannini, C.S. Baik
Journal: Annals of Oncology (2020)
The innate immune effector ISG12a promotes cancer immunity by suppressing the canonical Wnt/β-catenin signaling pathway
Authors: Rilin Deng, Chaohui Zuo, Yongqi Li, Binbin Xue, Zhen Xun, Yanxia Guo, Xiaohong Wang, Yan Xu, Renyun Tian, Shengwen Chen, Qian Liu, Jinwen Chen, Jingjing Wang, Xiang Huang, Huiyi Li, Mengmeng Guo, Xintao Wang, Miaomiao Yang, Zhihui Wu, Jinfeng Wang, Jiahuan Ma, Jun Hu, Guangdi Li, Songqing Tang, Zhengkun Tu, Hongbin Ji, Haizhen Zhu
Journal: Cellular and Molecular Immunology (2020)
13P Synergistic activity of PARP inhibitor and ATR inhibitor in melanoma cell lines may depend on BRAF-V600 mutation status
Authors: E.F. Giunta, V. Belli, S. Napolitano, V. De Falco, P.P. Vitiello, M. Terminiello, V. Caputo, P. Vitale, N. Zanaletti, D. Ciardiello, G. Argenziano, E. Martinelli, G. Martini, T. Troiani
Journal: Annals of Oncology (2020)
1214O Neoadjuvant durvalumab in resectable non-small cell lung cancer (NSCLC): Preliminary results from a multicenter study (IFCT-1601 IONESCO)
Authors: M. Wislez, J. Mazieres, A. Lavole, G. Zalcman, O. Carre, T. Egenod, R. Caliandro, R. Gervais, G. Jeannin, O. Molinier, M.A. Massiani, A. Langlais, F. Morin, F. Le Pimpec Barthes, L. Brouchet, J. Assouad, B. Milleron, D. Damotte, M. Antoine, V. Westeel
Journal: Annals of Oncology (2020)
1326P Liver metastasis but not bone metastasis impact overall survival of advanced non-small cell lung cancer (NSCLC) treated by nivolumab (GFPC 04-2016)
Authors: C. Decroisette, F. Guisier, O. Bylicki, R. Lamy, M. Geier, H. Morel, A. Bizieux, S. Vieillot, M. Bernardi, H. Janicot, L. Boissiere, G. Justeau, R. Gervais, H. Doubre, G. Le Garff, A. Vergnenegre, C. Chouaid
Journal: Annals of Oncology (2020)
359TiP International phase III trial: Balixafortide (a CXCR4 antagonist) + eribulin versus eribulin alone in patients with HER2-negative, locally recurrent or metastatic breast cancer (FORTRESS)
Authors: P.A. Kaufman, M. Martin, I. Mayer, L.T. Vahdat, S. Pernas Simon, P. Schmid, H.L. McArthur, R. Dent, H.S. Rugo, C. Barrios, A. Bobirca, F. Ringeisen, J. Cortés
Journal: Annals of Oncology (2020)
358TiP Phase Ib/II study of antibody-drug conjugate, sacituzumab govitecan, in combination with the PARP inhibitor, talazoparib, in metastatic triple-negative breast cancer
Authors: A. Bardia, L.M. Spring, D. Juric, A. Partridge, J. Ligibel, I. Kuter, J. Peppercorn, H. Parsons, P. Ryan, D. Chawla, V. Attaya, D.M. Fitzgerald, E. Viscosi, B. Lormill, M. Shellock, B. Moy, S.M. Tolaney, L.W. Ellisen
Journal: Annals of Oncology (2020)
Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial
Authors: Christopher C Parker, Noel W Clarke, Adrian D Cook, Howard G Kynaston, Peter Meidahl Petersen, Charles Catton, William Cross, John Logue, Wendy Parulekar, Heather Payne, Rajendra Persad, Holly Pickering, Fred Saad, Juliette Anderson, Amit Bahl, David Bottomley, Klaus Brasso, Rohit Chahal, Peter W Cooke, Ben Eddy, Stephanie Gibbs, Chee Goh, Sandeep Gujral, Catherine Heath, Alastair Henderson, Ramasamy Jaganathan, Henrik Jakobsen, Nicholas D James, Subramanian Kanaga Sundaram, Kathryn Lees, Jason Lester, Henriette Lindberg, Julian Money-Kyrle, Stephen Morris, Joe O'Sullivan, Peter Ostler, Lisa Owen, Prashant Patel, Alvan Pope, Richard Popert, Rakesh Raman, Martin Andreas Røder, Ian Sayers, Matthew Simms, Jim Wilson, Anjali Zarkar, Mahesh K B Parmar, Matthew R Sydes
Journal: The Lancet (2020)
823P Extended follow-up of a real-world cohort of patients (pts) with BRCA mutation (BRCAm) relapsed epithelial ovarian cancer (EOC) receiving olaparib maintenance therapy: The GINECO RETROLA study
Authors: T. de La Motte Rouge, L. Bengrine Lefevre, M-A. Mouret-Reynier, B. Asselain, B. Lucas, C. Gavoille, C. Cornila, D. Spaeth, E. Colomba, A. Patsouris, M. Fabbro, C. Chakiba, P. Toussaint, H. Simon, D. Berton, D. Garbay, C. Garnier Tixidre, D. Coeffic, O. Collard, C. Lefeuvre-Plesse
Journal: Annals of Oncology (2020)
1089P POD1UM-201: A phase II study of retifanlimab (INCMGA00012) in advanced or metastatic Merkel cell carcinoma (MCC)
Authors: G. Grignani, M. Burgess, R. Depenni, M. Guida, F. Spagnolo, F. Spada, F. De Braud, J. Pulini, S. Shankar, C. Tian, C. Lebbé
Journal: Annals of Oncology (2020)
162MO Neoadjuvant chemotherapy and immunotherapy in Luminal B BC: Results of the phase II GIADA trial
Authors: M.V. Dieci, V. Guarneri, G. Bisagni, A. Tosi, A. Musolino, S. Spazzapan, G. Moretti, G.M. Vernaci, T. Giarratano, M. Lo Mele, A. Rosato, G.L. De Salvo, P.F. Conte
Journal: Annals of Oncology (2020)
Pembrolizumab-Induced Thyroiditis and Colitis—Presentation and Resolution on Serial FDG PET/CT
Authors: Ayah Adel Nawwar, Julie Searle, Iain Douglas Lyburn
Journal: Clinical Nuclear Medicine (2020)

A 58-year-old man with previous melanoma of the left leg underwent whole-body 18F-FDG PET/CT to stage metastatic disease prior to commencing pembrolizumab. Follow-up FDG PET/CT after 3 months of treatment showed partial metabolic response of soft tissue and nodal metastases and diffuse increased thyroid and colonic uptake, suggestive of thyroiditis and colitis. Pembrolizumab was ceased, and a repeat FDG PET/CT scan showed regression of uptake in the thyroid gland and colon, in keeping with resolution of inflammatory change. Immune-related adverse events induced by Immune checkpoint inhibitors, such as pembrolizumab, should be recognized-cessation of treatment often leads to resolution.
784P Perioperative multimodality treatment in high-risk node-positive penile cancer: A single institution study of patients treated in a supraregional centre
Authors: C. Alifrangis, A.J.X. Lee, S. Fernando, O. Cakir, P. Koliou, A. Lerner, J. Forgenie, C. Akers, S. Harland, A. Freeman, M. Walkden, P. Hadway, H. Alnajjar, A. Muneer, A. Mitra
Journal: Annals of Oncology (2020)
1235TiP Perioperative pembrolizumab + platinum-based chemotherapy for resectable locally advanced non-small cell lung cancer: The phase III KEYNOTE-671 study
Authors: M. Tsuboi, A. Luft, G. Ursol, T. Kato, E. Levchenko, E. Eigendorff, H. Berard, B. Zurawski, I. Demedts, M.C. Garassino, J. Yang, K. Makarious, S.M. Keller, H.A. Wakelee
Journal: Annals of Oncology (2020)
1373P Difference in nephrotoxicity caused by cisplatin after a short or long hydration scheme in non-small cell lung cancer: A retrospective cohort study (HYCIS-XL)
Authors: K. Niggebrugge-Mentink, M. Beex-Oosterhuis, P. ter Horst, M. Van de Poll, H. Dieleman, C. Van Kesteren
Journal: Annals of Oncology (2020)